| Domain | Summary | Key details / ontology hints | Evidence |
|---|---|---|---|
| Disease definition | Microcephaly, short stature, and impaired glucose metabolism 2 (MSSGM2) is an ultra-rare Mendelian multisystem disorder linked to biallelic PPP1R15B dysfunction, with neurodevelopmental abnormalities and diabetes or impaired glucose metabolism as major manifestations. | Mendelian disorder; syndrome-level, disease-aggregated knowledge derived from published case reports and reviews. | (pqac-00000002, pqac-00000004, pqac-00000005, pqac-00000014) |
| Causal gene / protein | Causal gene: **PPP1R15B**; protein: **protein phosphatase 1 regulatory subunit 15B** / **CReP**, a regulatory subunit of an eIF2α phosphatase complex. | Pathway anchor: eIF2α dephosphorylation / integrated stress response (ISR). | (pqac-00000002, pqac-00000008, pqac-00000012, pqac-00000014) |
| Inheritance | Autosomal recessive. | Reported affected individuals carried homozygous missense variants; one index family was consanguineous. | (pqac-00000000, pqac-00000001, pqac-00000005) |
| Established variants | Best-established disease variant: **p.Arg658Cys (R658C)** in PPP1R15B. A later **p.Asn423Asp (N423D)** homozygous variant was reported with overlapping neurodevelopmental/growth features and impaired substrate recruitment; diabetes status was not established in the extracted evidence. | R658C impairs PP1 binding; N423D impairs eIF2 recruitment while preserving PP1 binding. Variant-class evidence is strongest for homozygous missense change(s); avoid overcalling broader allelic series from current sparse literature. | (pqac-00000002, pqac-00000008, pqac-00000011, pqac-00000013) |
| Core phenotype | Core syndrome comprises **microcephaly**, **short stature/growth retardation**, **intellectual disability/developmental delay**, and **impaired glucose metabolism/diabetes**. Additional reported findings include sensorineural deafness, delayed puberty, kyphoscoliosis, pectus excavatum, dental anomalies/oligodontia, sparse hair, hepatic fibrosis/cirrhosis, and hypothyroidism. | HPO suggestions: Microcephaly HP:0000252; Short stature HP:0004322; Intellectual disability HP:0001249; Diabetes mellitus HP:0000819; Sensorineural hearing impairment HP:0000407; Kyphoscoliosis HP:0002751; Pectus excavatum HP:0000767; Oligodontia HP:0000677. | (pqac-00000000, pqac-00000001, pqac-00000004, pqac-00000005, pqac-00000014) |
| Diabetes course | Diabetes has been reported from adolescence to adulthood in the primary family, with insulin dependence, negative type 1 diabetes autoantibodies, residual C-peptide, moderate insulin requirements, and ketosis in at least one patient. Reviews describe the glucose phenotype as late-onset relative to the congenital growth/neurodevelopmental features. | Reported ages at onset in extracted evidence: 15 years and 28 years. Insulin requirement examples: ~0.5 and ~0.7 U/kg/day. | (pqac-00000000, pqac-00000001, pqac-00000003, pqac-00000004) |
| Key mechanism | PPP1R15B/CReP normally helps PP1 dephosphorylate **eIF2α-Ser51**. Disease variants impair PP1 binding and/or eIF2 substrate recruitment, causing persistently increased eIF2α phosphorylation, dysregulated ISR/ER-stress signaling, impaired translation/secretory homeostasis, β-cell dysfunction, and apoptosis. | Cell/process hints: pancreatic beta cell (CL:0000169); endoplasmic reticulum stress GO:0034976; response to unfolded protein GO:0006986; regulation of translation GO:0006417; apoptotic process GO:0006915. | (pqac-00000002, pqac-00000006, pqac-00000007, pqac-00000008, pqac-00000012, pqac-00000013) |
| Diagnosis | Diagnosis is based on syndromic clinical recognition plus molecular confirmation of biallelic PPP1R15B variants, typically by exome sequencing with segregation confirmation. Supportive evaluations include diabetes phenotyping, neurodevelopmental assessment, hearing testing, and imaging/skeletal/endocrine workup as clinically indicated. | In the index report, exome sequencing, segregation filtering, and confirmatory Sanger/PCR-RFLP genotyping were used. Differential considerations include other ER-stress/monogenic diabetes syndromes such as Wolcott-Rallison syndrome. | (pqac-00000000, pqac-00000002, pqac-00000012) |
| Treatment | No disease-specific approved therapy or disease-targeted clinical trial was identified in the available evidence. Current care is supportive and phenotype-directed: insulin for diabetes, endocrine management, developmental/educational support, audiology, orthopedic care, dental care, and surveillance for liver/thyroid/puberty complications. | NCIT-style intervention hints: Insulin Therapy; Genetic Counseling; Physical Therapy; Occupational Therapy; Hearing Aid. These are management extrapolations, not validated disease-specific protocols. | (pqac-00000003, pqac-00000005, pqac-00000014) |
| Epidemiology | Extremely rare; available evidence supports only a very small number of reported individuals worldwide. No robust prevalence, incidence, carrier-frequency, or sex-ratio estimates were identified in the extracted sources. | Human evidence base includes the original two siblings plus later review-level mention of additional patients/affected siblings and one N423D patient with overlapping phenotype. | (pqac-00000004, pqac-00000011, pqac-00000015, pqac-00000016) |
| Evidence limitations | Knowledge remains constrained by very small sample size, incomplete longitudinal follow-up, review-level aggregation of some later cases, uncertain phenotype frequencies, and lack of disease-specific natural-history studies, treatment trials, or omics datasets. Some later features (e.g., hepatic fibrosis, hypothyroidism) are review-reported and not fully resolvable to individual primary cases from the extracted evidence. | Use cautious wording for penetrance, prognosis, and variant spectrum; avoid unsupported identifiers or precise epidemiologic estimates. | (pqac-00000004, pqac-00000005, pqac-00000014, pqac-00000015, pqac-00000016) |


*Table: This table condenses the most reliable current knowledge on PPP1R15B-related MSSGM2 for disease knowledge-base use. It highlights established facts, likely clinical annotations, and major evidence gaps from the small published case literature.*